Skip to content

NUPLAZID™ (pimavanserin): Innovation and Promise.

At ACADIA, we are developing NUPLAZID™ (pimavanserin) as a potential first-in-class treatment for Parkinson's disease psychosis (PDP). The successful results from our pivotal Phase III study suggest that NUPLAZID has the potential to transform the treatment landscape for these patients by providing an effective treatment of psychosis without compromising motor control and safety.


ACADIA Pharmaceuticals Reports Third Quarter 2014 Financial Results and Updates Timing of NUPLAZID™ NDA Submission

ACADIA Pharmaceuticals Receives FDA Breakthrough Therapy Designation for NUPLAZID™ (Pimavanserin) for Parkinson's Disease Psychosis

ACADIA Pharmaceuticals Announces Trade Name NUPLAZID™ for Pimavanserin

ACADIA Pharmaceuticals Announces Publication in The Lancet of Pivotal Phase III Parkinson's Disease Psychosis Trial with Pimavanserin

ACADIA Pharmaceuticals Announces Multiple Presentations of Data from Phase III Pimavanserin Program at the 17th International Congress of Parkinson's Disease and Movement Disorders

ACADIA Pharmaceuticals Announces Expedited Path to NDA Filing for Pimavanserin Following Meeting with FDA

ACADIA Announces Presentation of Data from Its Pivotal Phase III Parkinson's Disease Psychosis Study with Pimavanserin at the American Academy of Neurology Annual Meeting

ACADIA Announces Pimavanserin Meets Primary and Key Secondary Endpoints in Pivotal Phase III Parkinsons Disease Psychosis Trial

back to top